New research in Pediatric Dermatology reports several cases of shingles that developed at the original vaccination site in healthy children after they were immunized against chicken pox. Most of these...

First evidence of the shingles vaccine programme shows a substantial reduction in cases and long-term complications. A new study in the Lancet Journal of Public Health shows a substantial decrease in...

One week after Canadian officials approved GlaxoSmithKline’s shingles vaccine, Shingrix, the US Food and Drug Administration (FDA) gave the vaccine it’s approval. The FDA on Friday approved...

GlaxoSmithKline announced Friday that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Shingrix is a non-live, recombinant subunit...

GlaxoSmithKline announced Wednesday that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support...

NYU Langone Medical Center will lead a 5-year, 60-center clinical trial to evaluate new treatment protocols for herpes zoster ophthalmicus (HZO), a form of shingles that can seriously and permanently affect...

GlaxoSmithKline  announced this week that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Administration (FDA),...

GlaxoSmithKline (GSK) announced the publication of detailed results from a randomized phase III study (ZOE-70) of its investigational shingles vaccine, showing 90% efficacy in adults aged 70 years and...

By

Nearly 1 million incidences of herpes zoster, which is also known as shingles, occur every year in the U.S., with an estimated one-third of all adults affected by age 80. Despite its prevalence, particularly...

According to a report originated in the National Center for Immunization and Respiratory Diseases, infection with varicella zoster virus (VZV) causes two distinct clinical conditions. Primary VZV infection...